Eikon Therapeutics, Inc.
EIKNNext catalyst
EIK1001
Advanced Melanoma
Get an email about EIKN's next catalysts
Track Eikon Therapeutics (EIKN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
EIKN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.74 | FQ end Sep/2026 | Call: tbd
EIK1001 Phase 2 Est. Readout
Estimated primary completion for EIK1001 trial (NCT06246110) in NSCLC. Topline data typically follows completion by weeks to months.
SourceIMP1734 Phase 2 Est. Readout
Primary completion for IMP1734 trial (NCT06253130) in Advanced Solid Tumor
SourceMarket Overview
Stock performance and key metrics
EIK1001
Advanced Melanoma
Paclitaxel + Carboplatin
Non Small Cell Lung Cancer (Squamous or Non Squamous)
EIK1005
Advanced Solid Tumors
EIK1004-001 (IMP1707-001)
Advanced Solid Tumors
BDB001
Tumor, Solid
Association atezolizumab + BDB001+ RT
Solid Tumor, Adult
IMP1734
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EIK1001 | Phase 3 | Advanced Melanoma | - | - |
Paclitaxel + Carboplatin | Phase 3 | Non Small Cell Lung Cancer (Squamous or Non Squamous) | - | - |
EIK1005 | Phase 2 | Advanced Solid Tumors | - | - |
EIK1004-001 (IMP1707-001) | Phase 2 | Advanced Solid Tumors | - | - |
BDB001 | Phase 2 | Tumor, Solid | - | - |
Association atezolizumab + BDB001+ RT | Phase 2 | Solid Tumor, Adult | - | - |
IMP1734 | Phase 2 | Advanced Solid Tumor | - | - |
Frequently asked questions
What is in Eikon Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Eikon Therapeutics, Inc.'s (EIKN) pipeline across Phase 3, Phase 2. Its lead program is EIK1001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Eikon Therapeutics, Inc.'s next FDA catalyst?→
Eikon Therapeutics, Inc.'s (EIKN) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EIKN biotech catalysts?→
Add EIKN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Eikon Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.